OncoMatch/Clinical Trials/NCT06343311
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Is NCT06343311 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies EB103 for b-cell non-hodgkin's lymphoma (nhl).
Treatment: EB103 — This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Central Nervous System Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody
All subjects must have received an appropriate chemoimmunotherapy regimen which at a minimum includes an: Anti-CD20 monoclonal antibody
Must have received: anthracycline-containing chemotherapy regimen
All subjects must have received an appropriate chemoimmunotherapy regimen which at a minimum includes an: ... anthracycline-containing chemotherapy regimen
Cannot have received: CD19-targeted cellular therapy
Prior CD19-targeted cellular therapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Davis · Sacramento, California
- Baylor Scott & White Research Institute, Texas Oncology · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify